10月11日，CDE官网显示，恒瑞医药的EZH2抑制剂SHR2554片申报上市。这是首个申报上市的国产EZH2抑制剂。 SHR2554是恒瑞医药自主研发的新型、高效、选择 ...

Aberrant expression of G9a and NSD2 has been identified in multiple types of cancer. Therefore, dual-target inhibitors blocking both pathways may be considered a potential strategy to treat solid ...